BioCentury | Nov 9, 2015
Company News

Advanomics, Sunshine Biopharma deal

...Advanomics, which owns about 23% of Sunshine. The patent covers all rights related to Sunshine’s Adva-27a...
BioCentury | Dec 9, 2013
Company News

Sunshine Biopharma cancer news

...said it is reincorporating for acquisition opportunities and financing opportunities available to Canadian corporations. Sunshine's Adva-27a...
BioCentury | Sep 2, 2013
Company News

Advanomics, Sunshine Biopharma, Laboratoires Garmen Inc. deal

...parent company will acquire Garmen for an undisclosed amount. Garmen will manufacture 1 kg of Adva-27a...
...I trial of Adva-27a to treat breast cancer. Sunshine has an exclusive, U.S. license to Adva-27a...
...NanoQuebec and Canadian Institutes of Health Research (CIHR) to advance the development of the compound. Adva-27a...
BioCentury | Dec 3, 2012
Company News

Sunshine Biopharma, Institut National des Sciences Appliquees de Lyon deal

...Sunshine acquired from the French government research lab worldwide patents covering Sunshine's anti-cancer compound Adva-27a...
...from podophyllotoxin, their preparation and their applications. The company could not be reached for details. Adva-27a...
BioCentury | Jul 9, 2012
Clinical News

Sunshine Biopharma preclinical data

...In vitro, Adva-27a killed significantly more multidrug-resistant SCLC tumor cells than generic etoposide. Adva-27a is a...
...is a small molecule topoisomerase II (TOP2) inhibitor. Sunshine Biopharma Inc. (OTCBB:SBFM), Montreal, Quebec Product: Adva-27a...
BioCentury | Jul 18, 2011
Clinical News

Sunshine Biopharma preclinical data

...In vitro, Adva-27a was 16 times more effective at killing multidrug resistant human breast cancer cells...
...was 16 times more effective at killing multidrug resistant human breast cancer cells than etoposide. Adva-27a...
...is a small molecule topoisomerase II (TOP2) inhibitor. Sunshine Biopharma Inc. (OTCBB:SBFM), Montreal, Quebec Product: Adva-27a...
BioCentury | Jun 27, 2011
Company News

Sunshine Biopharma, Jewish General Hospital deal

...hospital partnered to conduct preclinical and Phase I testing of Sunshine's Adva-27a to treat cancer. Adva-27a...
BioCentury | Jan 31, 2011
Company News

Sunshine Biopharma, Binghamton University deal

...and university signed a three-year deal to conduct preclinical and Phase I testing of Sunshine's Adva-27a...
...IP developed under the deal. The university is eligible for royalties on the developed IP. Adva-27a...
Items per page:
1 - 8 of 8